Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C-Reference-Cited by-同舟云学术

Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C

Published:2010-04 Issue:4 Volume:54 Page:1647-1649
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Morello Judit¹,Soriano Vincent²,Barreiro Pablo²,Medrano José²,Madejón Antonio²,González-Pardo Gema¹,Jiménez-Nácher Inmaculada¹,González-Lahoz Juan²,Rodríguez-Novoa Sonia¹

Affiliation:

1. Laboratory of Pharmacology

2. Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

Abstract

ABSTRACT The influence of ribavirin trough concentrations (RBV C trough ) on the risk of hepatitis C virus (HCV) relapse was retrospectively analyzed in 99 HIV-HCV-coinfected patients who achieved end-of-treatment response with pegylated alpha interferon plus weight-based RBV. The independent predictors (odds ratio [OR] [95% confidence interval (CI)]) of HCV relapse were RBV plasma C trough of <2.5 μg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C trough may permit early adjustment of RBV dosage to avoid HCV relapse.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01399-09

Reference23 articles.

1. Aguilar Marucco, D., D. Gonzalez de Requena, S. Bonora, C. Tettoni, M. Bonasso, T. De Blasi, A. D'Avolio, M. Sciandra, M. Siccardi, L. Baietto, L. Trentini, A. Sinicco, G. Cariti, and G. Di Perri. 2008. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J. Antimicrob. Chemother.61:919-924.

2. Bani-Sadr, F., L. Denoeud, P. Morand, F. Lunel-Fabiani, S. Pol, P. Cacoub, C. Perronne, and F. Carrat. 2007. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J. Acquir. Immune Defic. Syndr.45:123-125.

3. Breilh, D., S. Djabarouti, P. Trimoulet, B. Le Bail, M. Dupon, J. M. Ragnaud, H. Fleury, M. C. Saux, R. Thiebaut, G. Chene, and D. Neau. 2009. Ribavirin plasma concentration predicts sustained virological response to peginterferon alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. J. Acquir. Immune Defic. Syndr.52:428-430.

4. Carrat, F., F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, A. Benzekri, P. Morand, C. Goujard, G. Pialoux, L. Piroth, D. Salmon-Ceron, C. Degott, P. Cacoub, and C. Perronne. 2004. Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA292:2839-2848.

5. Chan, A. H., N. Partovi, and M. H. Ensom. 2009. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C—a critical review. Ann. Pharmacother.43:2044-2063.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C;Antiviral therapy;2017

2. Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin;Therapeutic Drug Monitoring;2016-12

3. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study;PLOS ONE;2015-07-28

4. In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir;Infectious Diseases and Therapy;2014-12-17

5. Le Domaine des Co-infections et des Maladies Concomitantes du Réseau Canadien pour les Essais VIH des IRSC : Lignes Directrices Canadiennes pour la Prise en Charge et le Traitement de la Co-Infection par le VIH et l’Hépatite C chez les Adultes;Canadian Journal of Infectious Diseases and Medical Microbiology;2014